Centers | ||
|
|
|
Edinburgh Drug Discovery | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | EU-OPENSCREEN |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Partnerships |
Events |
Jobs |
GSK and MD Anderson to co-develop new cancer therapeuticsGlaxoSmithkline and MD Anderson Cancer Center entered into a co-development and license agreement to develop antibody based therapeutics to treat cancer. Under this agreement MD Anderson grants exclusive rights to antibodies developed during the... View all UCSF And Genentech to Develop Drugs to Treat Neurodegenerative DiseasesUniversity of California, San Francisco (UCSF) and Genetech have entered into a research collaboration to develop drugs to treat neurodegenerative diseases. Genetech will be providing funding to researchers at UCSF Small Molecule Discovery Center... View all Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all |
No EVENTS for listing |
No Job Posts |
